Nautilus Biotechnology (NAUT) Capital Expenditures (2020 - 2026)

Nautilus Biotechnology has disclosed Capital Expenditures across 7 years of filings, most recently posting $510000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $510000.0, up 132.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 7.44% YoY), and the FY2025 annual result was $1.3 million, down 39.82% from the prior year.
• Capital Expenditures came in at $510000.0 for Q1 2026 at Nautilus Biotechnology, up from $244000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $963000.0 in Q3 2022 to a low of $219000.0 in Q1 2025.
• The 5-year median for Capital Expenditures is $481000.0 (2022), against an average of $510294.1.
• Peak annual rise in Capital Expenditures reached 256.67% in 2022, while the deepest fall reached 76.77% in 2022.
• Nautilus Biotechnology's Capital Expenditures stood at $229000.0 in 2022, then jumped by 80.35% to $413000.0 in 2023, then tumbled by 38.5% to $254000.0 in 2024, then declined by 3.94% to $244000.0 in 2025, then surged by 109.02% to $510000.0 in 2026.
• The last three Capital Expenditures figures came in at $510000.0 (Q1 2026), $244000.0 (Q4 2025), and $418000.0 (Q3 2025), per Business Quant data.